References
- Camargo CA, Smithline HA, Malice MP etal A randomized controlled trial of intravenous montelukast in acute asthma. Am Respir. Crit. Cate. Med. 167, 528–533 (2003).
- Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifingthe leukotriene pathway. N Engl. J. Med. 340, 197–206 (1999).
- Pizzichini E, Leff A, Reiss TF etal Montelukast reduces airway eosinophilic inflammation in asthma: a randomized controlled trial. Eur Respir. J. 14, 12–18 (1999).
- Knorr B, Matz J, Bernstein JA et al Montelukast for chronic asthma in 6 to 14 year-old children: a randomized, double-blind trial. JAIVIA 279, 1181–1186 (1998).
- Lofdahl CG, Reiss TF, Leff JA eta]. Randomised placebo-controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BE Med. 319, 87–90 (1999).
- Dockhom RJ, Baumgartner RA, Leff JA etal Comparison of the effects of intravenous and oral montelukast on airway function: a double-blind, placebo-controlled, three period, crossover study in asthmatic patients. Thorax 55, 260–265 (2000).
- Virchow JC, Prasse A, Naya I eta]. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. j Respir. Cat. Cate Med. 162, 578–585 (2000).
- Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in theemergency department. Am. j Respir. Cat. Cate Med. 161, 1862–1868 (2000).
- Halpern MT, Khan ZM, Stanford RII eta]. Asthma: resource use and costs for inhaled corticosteroid verses leukotriene modifier treatment-a meta-analysis. j Fain. Pract. 52, 382–389 (2003).
Websites
- www.ginasthma.com (Accessed September, 2003).